AV 1142742

Drug Profile

AV 1142742

Alternative Names: AV1142742; RhuDex

Latest Information Update: 13 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; MediGene Ltd
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action B cell inhibitors; CD80 antigen inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Autoimmune disorders; Rheumatoid arthritis

Most Recent Events

  • 13 Oct 2015 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in United Kingdom (PO)
  • 13 Oct 2015 Discontinued - Phase-II for Rheumatoid arthritis in United Kingdom (PO)
  • 13 Aug 2015 No recent reports on development identified - Phase-I for Autoimmune disorders (In volunteers) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top